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Abstract
In recent years, there have been growing concerns on the issue of parallel trade on
pharmaceuticals. It is an existing issue in European Union and an emerging issue in the
North America and Asia. In this paper, a model is developed to explore the impact of
parallel trade on: 1) profits of pharmaceutical firms, 2) drug price, supply and social
welfare in the importing country, and 3) drug price, supply and social welfare in the
exporting country. The possible policy reactions of the governments in the two countries
are also discussed. By relaxing some assumptions, I extend the existing studies to a more
general framework. I found that firm’s total profits and social welfare in the importing
country may increase or decrease. This finding is contradicted to an existing study
because of the relaxation on some assumptions. Parallel trade will lead to a higher drug
price and then a social welfare loss in the exporting country; under certain circumstances,
the pharmaceutical firm may cut off the drug supply. The results show that the negotiated
price in the presence of parallel trade is sensitive to the market size of the drug and
transaction cost of parallel trade. Therefore, those factors have important policy
implications to the policy maker in the exporting country. For the importing country, the
social welfare change when parallel trade is legally permitted is closely related to the
firm’s bargaining power in the foreign market, which should be considered by the policy
maker.
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1. Introduction
In most industrialized countries, the GDP share of total health care costs has
grown rapidly in recent years. Among the health care costs, pharmaceutical cost has
increased at a more rapid rate than that of any others. Therefore, more and more attention
is being been paid to pharmaceutical issues.
Pharmaceutical prices vary significantly between countries, even among those at
the same level of development. This price disparity derives mainly from two sources: 1)
the difference in pharmaceutical price regulations between countries 2) the difference in
the demand for pharmaceuticals between countries.
In recent years, governments have become more and more involved in the
financing of health care. Under increasing budgetary pressures, governments have strong
incentives to reduce health care and pharmaceutical costs. Pharmaceutical price control in
many countries is a reflection of this situation. Pharmaceutical price control can take
many forms, such as direct price control (as in Canada, France, Italy and Spain),
reference pricing, compulsory licensing (as in Canada before 1987), and others. Price
control is commonly believed to be an important factor that leads to the pharmaceutical
price discrepancy between countries. For example, pharmaceutical prices in Canada have
been regulated by the Patented Medicine Price Review Board (PMPRB) since 1987.
Meanwhile, there is no such regulation in the U.S. During that same period, the average
U.S. price for patented drugs has been 36 percent to 67 percent higher than the average
Canadian price 1 . Although differences in the health care systems, income levels and other
country-specific factors could contribute to this price discrepancy, many researchers
believe that price regulation in Canada plays an important role.
At the same time, countries vary in the characteristics of their health care systems,
income levels, and other country-specific factors such as physician and patient
behaviours, also population health status. These factors lead to differing demands for
pharmaceuticals between countries and hence to the differences in drug prices.
The arbitrage opportunity resulting from price discrepancies opens the door to
parallel trade. Parallel trade is the importation of pharmaceuticals from a country where
prices are low to a country where price are high without the authorization of a trademark,
copyright, or patent holder. Parallel trade is legally permitted inside the European Union.
For example, in the United Kingdom, the Department of Health encourages pharmacists
to buy parallel imports when they are cheaper than domestic products. Fifteen percent of
domestic pharmaceutical consumption is imported from Spain and Italy. Parallel trade is
used as a policy tool to contain pharmaceutical costs in the health care system. Although
parallel trade is not legally permitted in North America, it is an emerging issue. Because
of the price discrepancy between the United States and Canada, more and more
Americans buy their prescription drugs from Canadian pharmacies, either by on-line
ordering or organized tours. As a result of public outrage over the drug price differential
between the two countries, in 2000, the US congress passed the Medicine Equity and
Drug Safety Act, which would allow Canadian drugs to be re-imported into the US.
President Clinton vetoed the legislation, ostensibly for safety reasons. However, this
remains an important policy issue both in the US and Canada, reflected, for example, in
1

See the article “Prescription Drug Prices in Canada: What Are the Lessons for the U.S.?” by Gross D.
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Health Canada’s suppression of internet pharmacies in 2004, and another round of hot
debate on the same issue in the 2004 presidential election campaign in the U.S.
The presence of parallel trade in pharmaceuticals causes strategic reactions of
pharmaceutical firms, which raise several interesting questions: 1) the change of firm’s
profits in the presence of parallel trade 2) drug price, supply and social welfare in the
importing country 3) drug price, supply and social welfare in the exporting country
With this paper, I would like to contribute to the ongoing analysis and debate over
issues related to parallel trade, and pay particular attention to the above three questions. I
will explicitly take into account the feature of different demands on pharmaceuticals
between countries, and pharmaceutical price control in the exporting country. The
analysis will be conducted through a two-stage game approach, in which the first stage is
a Nash bargaining game on the drug price between the pharmaceutical firm and the
government in the exporting country, and the second stage is a Cournot competition
between the firm and parallel trader in the importing country.
The analysis is organized as follows. In the next section, I will review a few
studies related to my work. The third section presents my model. The final section
contains my conclusions, policy implications, and discussion.
2. Literature Review
The literature is not large, but it has been growing rapidly in recent years. To date,
most of these are studies from a policy perspective without a rigorous theoretical
foundation. I review the three theoretical studies most related to my work.
Pecorino (2002)
This paper is a direct response to the legislative debate about whether the US
should allow low price prescription drugs to be reimported from Canada. In this paper, a
model is developed in which a drug is sold in both a foreign and a home country. When
parallel trade is not allowed, the monopolistic pharmaceutical firm sets MR equal to MC
in its home market to determine the optimal price, and the price in the foreign country is
the solution of a Nash Bargaining game between the firm and the foreign government;
given by

Max
[kCS ( p* )]α [kπ ( p*)]1−α ,
*

(*)

P

where CS is the consumer surplus in the foreign country, and π is the firm’s profit in the
foreign country. The author assumes that the demands in the two countries are identical
in all aspects except size, which is reflected by a scaling factor k. α measures the
bargaining power of the foreign government. When parallel trade is permitted, the author
assumes that there will be a uniform price in the two markets. This price is the solution to
the problem

Max
[kCS ( p* )]α [(1 + k )π ( p*) − π m ]1−α , (**)
*
P

Here, (1 + k )π ( p*) is the firm’s total profit in both markets under the uniform price, and
π m is the firm’s profit if the drug is sold only in the home market, with no supply to the
3

foreign country. Pecorino analyses two different cases: linear demand and constant
elasticity of demand. In both cases, the author finds that both the firm’s profit and the
domestic consumer surplus rise when parallel trade is legally permitted. That is because
the firm bargains harder on the price under parallel trade. That implies the negotiated
price under parallel trade has to be higher than in the absence of parallel trade, otherwise,
there will be no supply to the foreign market.
There are two important assumptions in this model. First, the assumption of
identical demands in the two countries is crucial to the conclusion about the firm’s profit.
The author has made this assumption based on the fact that the countries (EU, Canada,
Japan, etc.) in question are all highly developed countries with similar levels of income.
Therefore, the drug price discrepancy between countries occurs only because of drug
price control. However, price control is only one of the reasons that lead to drug price
discrepancy between countries; different demand between them is also an important
factor. For example, the drug price discrepancy between Portugal and U.K is caused not
only by price regulation, but also by differences in income between the two countries.
Furthermore, in considering the different characteristics of health care systems and drug
insurance coverage (public and private), identical demands (i.e. same demand elasticity
and maximal willingness to pay) between countries is a questionable assumption, even
for those countries at the same level of development. Therefore, identical demand can
only be regarded as a special case. Second, the assumption of uniform price in both
countries in the presence of parallel trade may also be unrealistic. Price in the importing
country is related to the parallel trader’s costs, a fact that has important policy
implications. And also, the parallel trader has to face the price competition from the
manufacture in the importing country.
Ganslandt and Maskus (2004)
In this paper, the authors develop a model in which a manufacturer competes in its
home market with parallel trade firms. The home country is the high price country and
the foreign country is the low price country. In the foreign country, the pharmaceutical
prices are regulated. A distinct feature of this model is that multiple parallel traders
jointly choose the maximum amount of parallel trade. It is a three stage game. At the first
stage, n symmetric parallel importers enter the market, applying for a license from the
authority in the home country at a cost T. Parallel traders will enter the market if the
expected profit is non-negative. At the second stage, each parallel trader chooses its own
quantity based on the regulated price in the foreign country and the transaction cost t. At
the final stage, the manufacturer sets its price in the home country by taking into account
the amount of parallel trade. The model is solved by backward induction. If the trade
costs (T and t) are not too high, the manufacturer will accommodate the parallel trade.
The equilibrium number of parallel traders and quantity of parallel trade can be found.
The price in the home market is lower than in the absence of parallel trade. Using data
from Sweden, the authors found that the prices of drugs subject to competition from
parallel trade fell relative to other drugs over the period 1994-1999. The econometric
analysis confirms the theoretical prediction.
The most important feature of this model is the limited quantity of parallel trade.
The quantity is jointly determined by the manufacturer and parallel traders. This will not
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lead to a uniform price in two countries under parallel trade as is assumed in Pecorino.
Therefore, it makes the model more realistic.
Nevertheless, this analysis is “one-sided”. The authors consider only the price
change and the reactions of the interested parties in the home market. They do not
examine the impact of parallel trade on the foreign market (i.e. the price and supply of the
drug, and social welfare). Moreover, this analysis ignores the influence of foreign
demand (and hence manufacturer’s profit in the foreign market) on the manufacturer’s
decision in the home market, as well as the interaction between the foreign government
and the manufacturer.
Jelovac and Bordoy (2005)
In this paper, the authors consider the changes of price and welfare after parallel
trade is legally permitted. There are two important features of their model. First, the two
countries have different demands. Country i’s demand is Di = θi − α i pi , where θi reflects
the different value that consumers put on the drug and α i reflects the difference in the
patients’ level of co-payment. Second, the consumer puts a lower value on the reimported
drug than on the one originally offered by the manufacturer, so their prices are not the
same. The model is a three stage game. At the first stage, the firm maximizes its profit by
taking into account parallel trade. At the second stage, the parallel importer sets a price to
maximize his profit. At the final stage, the consumers in each country choose to consume
one unit of the drug supplied either by the monopolist or by the parallel trader, depending
on the price. The game is solved by backward induction. The equilibrium has several
interesting characteristics. First, prices tend to converge under parallel trade, that is, the
price in the low price (exporting) country is higher and the price in the high price
(importing) country is lower than without parallel trade. Second, the effect of parallel
trade on the total welfare is ambiguous except for a few extreme cases. Third, the
different co-payment rates have an influence on parallel trade.
Modifying two aspects of this model may have important implications for the
impact of parallel trade. The first is price regulation. In Jelovac and Borday assume that
the firm can freely set a price. However, many studies argue that low price (which gives
the incentive to parallel trade) is the result of price regulation. When a firm reacts to
parallel trade under circumstances of price regulation, and its power to set a price is
limited, the story might be different. Second, in this paper, the total welfare is defined
as TW = CS A + CS B − PE A − PEB + π m + π w , where PE is the public expenditure paid by
the government, and the last two terms are the profit of the monopolist firm and parallel
trader. However, in the long run, total welfare is much more difficult to define if we take
into account some other concerns such as R&D of pharmaceuticals.
In general, among the existing studies, very few have focused attention on the low
price (exporting) country. Their analyses deal mainly with the price and welfare in the
importing country. However, if parallel trade were legally permitted, the consequences
for the low price country are also very important. Parallel trade will affect the profits of
the pharmaceutical industry, and the reactions of that industry could have an impact on
the national pharmaceutical price control system, on the drug supplies, and more
generally on price negotiations between the pharmaceutical industry and each
government. If a compromise on price cannot be reached, the pharmaceutical
5

manufacturer may cut off the supply of the drug to that market. For example, Danzon
(1998) notes that Glaxo delayed for several years to launch its antimigraine product
sumatriptan (Imigran®) in France, rather than accepting a low price that would have
undercut its higher price elsewhere.
The model I develop below makes a series of contributions:
(1) I consider the impact of parallel trade on drug price, supply, and associated social
welfare in the low-price (exporting) country; social welfare in the importing country; and
the firm’s total profit.
(2) I consider not only price control in the low-price country, but also the influence of
the different characteristics of the demand in the two markets on the question of a firm’s
decision, its profit and the equilibrium price in the exporting country.
(3) I consider in more detail on possible policy reactions of the government in the lowprice country and explore potential policy options for the high-price country.
3. A Model of Parallel Trade
Assumptions
I assume that there are two countries, H and L. A monopolistic pharmaceutical
manufacturer produces and sells a patented drug in both H and L. The pharmaceutical
prices are regulated in country L. The price of this drug in country H ( pH ) is higher than
the price in country L ( pL ). The manufacturer is located in H. For simplicity, it is
assumed that the firm produces at zero cost. In addition, the demands for this drug are
different in the two countries. Demand is q = 1 − pH in country H, and qL = α − pL in
country L. pH and pL are the price of this drug in country H and country L respectively.
α is assumed to be smaller than 1, so that the monopoly price in country H is higher than
the monopoly price in country L. Since the two demands have same slopes, α is an
unambiguous measure of market size. These demand specifications are tractable and
allow me to determine the influence of market size. Without parallel trade, the firm acts
as a profit-maximizing monopolist in country H, setting its marginal revenue equal to the
marginal cost. For the given demand function, the monopoly price for the firm is ½, q is
½ and profit ( π m ) is ¼. In country L, pharmaceutical price is lower than that in country
H. The price in country L is determined in a bargaining process between the firm and the
government of country L. If parallel trade is allowed, the parallel trader purchases the
drug in country L at the negotiated price pL , and ships it to country H with a transaction
cost t. This t is assumed to be less than ½, since parallel trade is clearly impossible if it is
higher. In contrast to the assumption of multiple parallel traders in Ganslandt and
Maskus (2004), I assume a single parallel trader. Once again, this is for the ease of
calculation 2 . Under parallel trade, total sales in country H are q = qH + qT , where qH is
the quantity sold by the firm and qT is the quantity sold by the parallel trader. The profit
of the parallel trader is denoted π T ; the profit of the firm in country H under parallel
trade is denoted π H and its profit in country L is denoted π L .

2

This simplification does not change the direction of the fundamental conclusions.
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An equilibrium under parallel trade consists of the quantities qL , qH and qT and
the prices pL and pH . The equilibrium is obtained in two stages. In the first stage, the
firm and the government in country L negotiate the price of the drug pL , which is the
solution of a generalized Nash Bargaining game. In the second stage, in country H, the
monopolist and the parallel trader engage in Cournot competition which determines the
equilibrium price pH and the quantities qH and qT . 3 The firm and the parallel trader,
taking each other’s sale as given, choose their own sales so as to maximize their own
profits. The price pH is the highest price at which all of the drug can be sold. Also, qL is
the quantity of goods demanded by the consumers in country L when the price is pL . As
usual, the equilibrium is solved by backward induction.
Cournot Competition in Country H
Under parallel trade, the firm’s profit in market H is π H = pH qH + pL qT . The first
term is the profit made from the firm’s own sale in market H, and the second term is the
profit made from the sale to the parallel trader. The parallel trader buys this drug at pL in
country L and sells it at pH in country H. Given the demand functions, the firm’s profit
is
π H = [1 − (qH + qT )] qH + pL qT
(1)
The parallel trader’s profit is
π T = [1 − (qH + qT ) − pL − t ] qT

(2)

The firm and the parallel trader, taking each other’s sale as given, choose their own sales
so as to maximize their own profits. Solving out the Cournot equilibrium,
1
⎧ 1 + pL + t
if pL ≤ − t
⎪⎪
3
2
qH = ⎨
⎪1
otherwise
⎪⎩ 2

(3)

1
⎧ 1 − 2( pL + t )
if pL ≤ − t
⎪
3
2
qT = ⎨
⎪0
otherwise
⎩

(4)

1
If the price of the drug in country L is higher than − t , there would be no parallel trade
2
because the acquisition cost to the parallel trader is too high.
3

The idea is that the parallel trader and the firm have to compete with each other. We can change the
assumption as the firm being a Stackberg leader, which will change the specific solutions of the model, but
it does not change the direction of the conclusion.
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The highest price pH at which all of the goods can be sold is:
⎧ 1 + pL + t
⎪⎪
3
pH = ⎨
⎪1
⎪⎩ 2

if pL ≤

1
−t
2

(5)

otherwise

Substituting equation (3), (4) and (5) into equation (1), the firm’s profit in country H is
1
⎧
2
⎪⎪ ⎡⎣(1 + pL + t ) + 3 pL (1 − 2 pL − 2t ) ⎤⎦ / 9 if pL ≤ 2 − t
πH = ⎨
⎪1
otherwise
⎪⎩ 4

(6)

Parallel trade keeps π H below ¼ until the price in market L is high enough to drive out
1
the parallel trader. As pL approaches − t from below, qH , pH and π H converge to the
2
monopoly solution while qT and π T converge to zero. There are no discontinuities in any
of the variables when the parallel trade drops out of the market.
The firm’s profit in country L is
⎧⎪(α − pL ) pL if pL ≤ α
otherwise
⎪⎩ 0

πL = ⎨

(7)

The firm’s total profit in both markets is π = π H + π L . Clearly, π L is increasing in α and
α
is maximized at pL = . Differentiation shows that π H is increasing in pL and t
2
1
when pL ≤ − t .
2
∂π H
1
= (5 − 10 pL − 4t ) / 9 > 0 if pL ≤ − t
(8)
∂pL
2

∂π H
1
= (2 − 4 pL + 2t ) / 9 > 0 if pL ≤ − t
∂t
2

(9)

Functions π L and π H are both continuous; π L is concave over the domain 0 ≤ pL ≤ α ,
1
and π H is concave over the entire domain. And π H is always kinked at pL = − t .
2
First Stage

8

At the first stage, the firm and the government in country L negotiate the price pL .
Like Pecorino (2002), I assume that the negotiated price is determined by a generalized
Nash bargaining game. The pay-off of the government in country L is the consumer
surplus gained by the consumers if the good is made available in market L, and the firm’s
pay-off is the difference between its profits if it sells in both markets ( π ) and its profit if
it sells only in market H ( π m ). If they agree on a price, that price maximizes a weighted
geometric average of their pay-offs, where the weights reflect bargaining power. If the
firm cannot attain profits of at least π m by selling in both markets, it will not agree to sell
in market L.
The price chosen is determined by the following generalized Nash bargaining
game:
1−γ

⎡
⎤
[CS ( pL )] ⎢π ( pL ) −π m ⎥
Max
pL
⎣
⎦

(10)

1
CS(pL )= (α − pL ) 2
2

(11)

γ

where

In equation (10), γ is the bargaining power of the government in country L ( 0 < γ < 1 );
π m is ¼.
Figure-1, circumstances of no agreement between the firm and government L
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For every γ , there are some circumstances in which there will be no agreement
between the firm and government L. If the market size in country L ( α ) is so small that
the firm’s best profits when it sells in both markets are smaller than π m , the firm will cut
off the supply to market L. This situation is illustrated by Figure 1.
1
There are some α (smaller than − t ) such that the firm’s best profits when it
2
sells in both markets under parallel trade are just equal to π m . Call this value α * and let
pL* be the associated profit-maximizing price. 4 If α falls below α * , profits in both
markets are smaller than π m

at every pL that is smaller than α . Since the firm’s

maximal total profits in the two markets are smaller than π m , the firm will cut off the
supply to market L. If α rises above α * , profits are greater at every pL that is smaller
than α , and there will be an agreement that benefits both parties. Henceforth α will be
assumed to lie between α * and 1 so that there is an agreement.
Next, I analyze the equilibrium in three different cases: γ = 0 , γ = 1 and 0 < γ < 1 .
Case 1: γ = 0
When γ = 0 , all the bargaining power resides with the firm. The generalized Nash
Bargaining game simplifies to the firm’s profit maximization. The firm acts as a
monopolist in market L and can freely choose the price pL to maximize π . There are two
components in the firm’s total profit π : profit in market L ( π L ) and profit in market H
( π H ). Based on equation (6) and (7), the solution of the firm’s profit maximization is

⎧α
⎪2
⎪
⎪ 1
pL = ⎨ − t
⎪ 2
⎪ (5 + 9α − 4t )
⎪
28
⎩

if α > 1 − 2t
8
if 1 − t < α < 1 − 2t
3
8
if α < 1 − t
3

(12)

The intuition behind equation (12) is as follows.
α
α
1
(a) The monopoly price in market L is . If is greater than − t , the profit function
2
2
2
looks like that in Figure 2. The firm maximizes its profits by charging the monopoly price
in both markets; the gap between the two monopoly prices is too small to allow the
parallel trader to operate.
4

The firm’s best profit is achieved when it has all the bargaining power and can freely choose the price to
maximize its profits. In this context, by setting π L + π H = 1/ 4 , we can find

α * = ⎡ 2 14(5 / 4 − t 2 − 2t ) − 5 + 4t ⎤ / 9
⎣

⎦
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(b) If

α
2

is between

1 4
1
− t and − t , the profit function looks like that in Figure 3.
2 3
2

When the price pL exceeds

α

, the firm’s profit in market L begins to fall, but the firm’s
2
profit in market H increases since the higher pL reduces the quantity of parallel trade.
The increase of π H outweighs the fall of π L . Therefore, the optimal price for the firm
1
“hangs up” at − t .
2

α

1 4
is smaller than − t , the profit function looks like that in Figure 4. The optimal
2
2 3
α
price for the firm is pL = (5 + 9α − 4t ) / 28 . When the price pL exceeds , the firm’s profit
2
in market L begins to fall, but its profit in market H increases. The fall of π L is smaller
than the increase of π H if pL < (5 + 9α − 4t ) / 28 , and greater than the increase of π H
if pL > (5 + 9α − 4t ) / 28 . At pL = (5 + 9α − 4t ) / 28 , the absolute values of the slopes of π L
and π H are equal. Therefore, the optimal price for the firm is pL = (5 + 9α − 4t ) / 28 .

(c) If

Figure-2, large market in country L
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12

How does the price vary with α and t? An examination of equation (12) shows
∂p L
1
∂p
is positive as long as pL ≠ − t , and L is positive so long as there is parallel
that
∂t
∂α
2
trade.
An increase in α for a given t increases the equilibrium price pL except when α
8
is still in the range of 1 − t < α < 1 − 2t , over which the equilibrium price pL hangs up
3
at 1/ 2 − t . A larger market size allows the firm to charge a higher price. In Figure 2 and
Figure 4, an increase in α increases the slope of π L and hence π at each pL , so that the
stationary point lies farther to the right: equilibrium pL rises with α . Whenever α is still
8
in the range of 1 − t < α < 1 − 2t , the analysis in part (b) above continues to hold.
3
Therefore, the equilibrium price pL hangs up at 1/ 2 − t .
Similarly, a decrease in t (for a given α ) in the presence of parallel trade makes
the graph of π H and then π steeper at each pL , shifting the stationary point to the right,
so that the equilibrium price rises as the transaction cost falls. A falling transaction cost
increases competition from the parallel trader, so the firm raises pL to limit the parallel
trader’s activity.
What are the effects of a change in α or t on the firm’s total profits? Recall that
∂π ∂π L
∂π ∂π H
=
> 0 whenever there is
=
> 0 whenever pL is less than α . Likewise,
∂t
∂t
∂α ∂α
parallel trade. An increase of α increases the firm’s profit in market L at each pL
smaller than α , and hence the firm’s maximal total profits must also rise. Under parallel
trade, an increase of t reduces the quantity of parallel trade, so that the firm’s profit in
1
market H increases. When pL = − t , the increase of t means that the firm could charge a
2
lower price that is closer to the monopoly price α / 2 in market L, so that the firm’s profit
in market L increases. The increase of t shifts the graph of π upward at each pL smaller
1
1
than − t , so long as pL is initially below − t . Consequently, the firm’s maximal
2
2
profits rise.
The consumer surplus in country L is given by equation (11). Differentiation
shows that
∂CS ( pL )
∂p
= (α − pL )(1 − L ) > 0
∂α
∂α

(13)

∂CS ( pL )
∂p
= (α − pL )(− L ) < 0
∂t
∂t

(14)
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∂p L
is always smaller than one, an increase of α
∂α
in country L must increase the consumer surplus. Similarly, since an increase of t in the
presence of parallel trade decreases the equilibrium price pL , it must increase the
consumer surplus in country L.

whenever there is parallel trade. Since

Case 2: γ = 1
When γ = 1 , all the bargaining power resides with the government in country L.
From equation (10), we can see that the problem is simplified to the maximization of
consumer surplus in country L. The government in country L will choose the lowest price
that the firm will accept, which is the price that sets π − π m = 0 :
⎡
5 ⎤
pL = ⎢(5 + 9α − 4t ) − (5 + 9α − 4t ) 2 + 56(t 2 + 2t − ) ⎥ / 28
4 ⎦
⎣

(15)

This pL is the point at which the profit function π in Figure 2, 3 and 4 cuts the line with
height ¼. An increase of α or t shifts the graph of π upward; therefore, the intersection
of the profit function π and line of ¼ moves left. The new equilibrium price is lower
than before. 5 If the market size in country L is bigger, the firm’s lowest acceptable price
would be lower. A larger market in country L make it easier for the firm to compensate
its profit loss in country H. Higher transaction costs reduce the quantity of parallel trade
and hence the profit loss in country H; therefore, the firm’s lowest acceptable price in
market L is decreasing in t. Since the consumer surplus in country L is increasing in α
and decreasing in pL , a larger α or t increases consumer surplus.
Case 3: 0 < γ < 1
When the bargaining power is between 0 and 1, we should have the same three
cases as we saw when the firm has all the bargaining power. When the market size is
large and firm has high bargaining power, the equilibrium pL could be large enough to
−
prohibit parallel trade. When the market size is relatively small and the firm has low
1
bargaining power, the equilibrium pL is below − t , the firm accommodates parallel
2
1
trade. The intermediate case is that the firm chooses a price hanging up at − t . It is
2
difficult to explicitly solve out the equilibrium price for the general case. But we can
explore the property of the equilibrium price as follows. If the price is greater than or
1
equal to − t , there will be no parallel trade. Therefore, I focus my analysis only on the
2
5

The effects of a change in

α

or t on the equilibrium price

pL can also be shown by differentiations,

please see the details in Appendix 1 and Appendix 2.
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1
case where the price is smaller than − t , i.e. the firm accommodates parallel trade. The
2
first and second order conditions of equation (10) are

⎡

⎤

⎣

⎦

γ CS '( pL ) ⎢π ( pL ) − π m ⎥ + (1 − γ )π '( pL ) CS ( pL ) = 0

(16) 6

⎡
⎤
Γ ≡ γ CS "( pL ) ⎢π ( pL ) − π m ⎥ − CS '( pL )π '( pL )+ (1 − γ )π "( pL ) CS ( pL ) < 0
⎣
⎦
(17)
where the prime denotes a derivative. Totally differentiating equation (16), we get
⎡
⎤
−CS '( pL ) ⎢π ( pL ) − π m ⎥ + π '( pL )CS ( pL )
dpL
⎣
⎦
=
<0
(18)
dγ
Γ
The negotiated price is decreasing in the bargaining power of the government of country
L.

dpL
=
dt

−γ CS '( pL )

d π ( pL )
dπ '( pL )
− (1 − γ )CS ( pL )
dt
dt
<0
Γ

(19)

The negotiated price is decreasing in the transaction cost of the parallel trader. With a
higher transaction cost, the quantity of parallel trade is lower; this means a smaller profit
loss in the high price market; therefore, the firm is more willing to accept a lower
negotiated price in the low price market.
⎡
⎤ dCS '( pL )
dπ ( pL )
dπ '( pL )
dCS ( pL )
−γ ⎢π ( pL ) − π m ⎥
− γ CS '( pL )
− (1 − γ )
CS ( pL ) − (1 − γ )π '( pL )
dα
dα
dα
dpL
⎣
⎦ dα
=
Γ
dα

(20)
dpL
dp
< 0 and lim L > 0 . That means that a larger market size leads to a
γ
→
0
dα
dα
lower negotiated price if the government in country L has high bargaining power. With a
larger market size in country L, it is easier for the firm to recover the profit lost in
country H. Therefore, the firm is more willing to accept a lower price in the negotiation.
When the firm has high bargaining power, it will try to take advantage of price
discrimination and charge a higher price. A relatively larger market will be more likely to
accept a higher price.

Hence lim
γ →1

6

The result is based on equations (6) and (7) but expressed in general equation form for simplicity.
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The effects of a change in γ , α or t on a firm’s total profit are shown by the
differentiations:
dp
dπ
= π '( pL ) L < 0
dγ
dγ

(21)

dπ
∂p
= pL + π '( pL ) L > 0
dα
∂α

(22)

d π ∂π H
∂p
=
+ π '( pL ) L > 0
dt
∂t
∂t

(23)

The firm’s profit is decreasing in the bargaining power of government L, and
increasing in the market size and the transaction costs to parallel trader. For the firm, the
benefits from an increase of α or t depend on its bargaining power. In both equation (22)
and (23), the first term is positive and the second term is negative. π '( pL ) is greater than
zero in the relevant range. π '( pL ) = 0 is only possible when the firm has all bargaining
power. Equations (22) and (23) are minimized to zero when the firm has zero bargaining
power. The firm’s profit is ¼ whatever the α or t is. As the firm’s bargaining power goes
up, the equilibrium price pL also goes up, and then π '( pL ) is smaller. Therefore, the
second terms in both equations are less negative.
Because the effect of a change in t on consumer surplus in country L is entirely
determined by its effect on pL , a larger t increases consumer surplus. If the government in
country L has most of the bargaining power, consumer surplus is increasing in α . If the
firm has most of the bargaining power, consumer surplus is also increasing in α since
∂pL
is always smaller than one.
∂α
A comparison between parallel trade and no parallel trade regimes
In the above analysis, we assume parallel trade is legally permitted in both
countries L and H. In this section, at first, I assume that parallel trade is not legally
permitted, and then compare firm’s profits and social welfare of the two countries if
parallel trade is legally permitted.
When there is no parallel trade, the firm and the government in country L solve
γ

1−γ

⎡⎣CS ( pLNT ) ⎤⎦ ⎡⎣π L ( pLNT ) ⎤⎦
Max
NT
pL

(24)
NT

where I denote the equilibrium price under no parallel trade regime as p L , for the given
demand, the solution of equation (24) is
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pLNT =

α (1 − γ )

(25)

2

The corresponding profit is

1 α 2 (1 − γ 2 )
4
4

π NT = +

(26)

If the two countries move from no parallel trade regime to parallel trade regime, we
are interested on the changes of firm’s profits and social welfare. In country L, if the only
concern of the government is consumer surplus, we just need to find out the change of
equilibrium prices between two regimes. In the presence of parallel trade, in order to
compensate the firm’s profit loss in country H, there must be an increase of price in
country L, ΔpL = pL − pLNT > 0 . And the magnitude of Δp depends on the bargaining
power of each party.

d ΔpL d ( pL − pLNT ) dpL α
=
=
+ >0
dγ
dγ
dγ 2

(27) 7

From the analysis in the last section, we know when γ = 0 , there is an increase of the
equilibrium price in market L in the presence of parallel trade, and we also
d Δp L
know
> 0 ; therefore, for any given value of γ , there is an increase of the negotiated
dγ
price in the presence of parallel trade ( ΔpL > 0 ). The increase of price has two effects:
increasing firm’s profit in country L, and reducing the quantity of parallel trade.
Therefore, the consumer surplus falls, and then the social welfare in country L is lower
under parallel trade. The higher the bargaining powers of the government in country L,
the larger the change in the equilibrium price, and hence the consumer surplus. Therefore,
parallel trade undermines the high bargaining power of the government in country L.
For 0 < γ < 1 , the impact of parallel trade on firm’s profit is ambiguous.
Differentiating Δπ with respect to γ , we have

d Δπ d (π − π NT ) dπ
γα 2
)
=
=
− (−
dγ
dγ
dγ
2
dp
dπ
where
= π '( pL ) L < 0
dγ
dγ

(28)

The firm’s profit is decreasing in the bargaining power of government L in both regimes:
with or without parallel trade. Therefore, both the first and second term in equation (28)
7

Please see the proof in appendix 3
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are negative. From the above analysis, we know the impact of parallel trade on the firm’s
profit at two extreme cases. When the firm has all bargaining power ( γ = 0 ), it suffers a
profit loss. The firm cannot fully take the advantage of price discrimination in the
presence of parallel trade. When the firm has no bargaining power at all ( γ = 1 ), its profit
is unchanged in the presence of parallel trade. Therefore, we have
d Δπ
d Δπ
< 0 , lim
=0
γ →0 d γ
γ →1 d γ

lim

(29)

The firm tends to have a larger profit when it has high bargaining powers ( γ → 0 ), since
its ability of price discrimination is undermined by the parallel trade. If the firm’s bargain
power is low ( γ → 1 ), the impact of parallel trade on firm’s profit is small.
Under parallel trade, the consumer surplus in country H is higher. The quantity of
supply goes up and price goes down with parallel trade. If the social welfare in country H
is simply defined as the sum of firm’s profit and consumer surplus, it could be higher
under parallel trade when the firm has low or no bargaining power in country L. When
the firm has high bargaining power in country L, the consumer surplus in country H is
still higher, but the firm will suffer higher profit loss; therefore, the effect on total social
welfare in country H is ambiguous.
A summary of the results is presented in Table 1.
4. Conclusion, Policy Implications, and Discussion
In the presence of parallel trade, the pharmaceutical firm has to compete with the
parallel trader in the high price market so that the profit of the firm in the high price
market falls. In order to compensate for the loss in the high price market, the firm will
bargain harder with the government in the low price country, and the price of the drug in
the low price country will rise. If the market size in country L is so small that the firm’s
best profits when it sells in both markets are smaller than π m , the firm will cut off the
supply to market L. Therefore, there will be a social welfare loss incurred from parallel
trade.
When the demands are different in the two markets and the pharmaceutical firm
has high bargaining power in the price negotiation, the firm’s profits fall because its
ability to price discriminate is undermined by parallel trade. The firm’s total profit is
maximized if it can fully take advantage of price discrimination. The result of an
increasing of the firm’s profits in Pecorino (2002) is the outcome of identical demands in
two markets, which implies that the only source of price differential is from price
regulation. However, when the price differential results not only from price regulation,
but also from different demands in the two markets, the firm suffers a profit loss under
parallel trade.
When the firm earns very little profit from the low price market because of low
bargaining power, the impact of parallel trade on its profit won’t be large. Under parallel
trade, the consumer surplus in the high price country goes up since the price of the drug is
lower. Therefore, the short run social welfare in the high price country could be higher if
the firm’s bargaining power in the low price country is low.
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Policy Implications

The government in country L
If the market size of the drug in country L is too small, the firm may cut off the
drug supply to country L. The decision is sensitive to α and t . If the market size is large
enough and the firm decides to accommodate parallel trade, as shown in the last section,
the negotiated price is also sensitive to α and t . Therefore, those factors have policy
implications for the government in country L.
When the government in country L has high bargaining power, the firm’s
minimum acceptable price in the presence of parallel trade is decreasing in α . The
government in country L has the power to influence α . For example, the government
could subsidize the target population of the drug in the question, manipulate the
consumer’s insurance status and co-payment rates, and put the drug on the formulary of a
public drug plan. Those actions will increase the maximal willingness to pay and
decrease the demand elasticity for the drug, so that the market will be more important and
attractive to the firm; therefore, it will be willing to accept a lower price in the
negotiation. When the government in country L has low bargaining power, the firm’s
optimal price in the presence of parallel trade is increasing in α . If the goal is a lower
price level, the government in country L could remove the drug from the formulary of a
public drug plan, or reduce the subsidy to the target population of this drug. A more
straightforward option in all cases is to manipulate the transaction cost to the parallel
trader. This action could achieve the same goal on the negotiated price without affecting
the demand and supply of the drug. An increase in the unit transaction cost to the parallel
traders will reduce the amount of parallel trade, and subsequently lead to a lower price
which is acceptable to the firm. One option is a unit tax (or regulation fee) on the parallel
exportation.
The government in country H
Before the presence of parallel trade, when the government in country L has all
the bargaining power, the firm obtains very little profit from market L. In the presence of
parallel trade, in order to induce the firm to supply the drug, the government in country L
has to offer a higher price. The firm’s total profit is the same as before. However, the
consumer surplus is increased in country H. That is similar to a transfer of consumer
surplus from country L to country H. The social welfare is higher in country H in the
presence of parallel trade. Therefore, if the drug price is strictly regulated in country L,
legalization of parallel trade could be a policy option for the government in country H to
undermine the foreign drug price regulation.
Before the presence of parallel trade, if the firm has high bargaining power in the
low price country and the demands are different in the two markets, the firm can take the
advantage of price discrimination to maximize its profit. If parallel trade is legalized in
the high price country, the firm’s capacity for price discrimination is undermined.
Therefore, it will suffer a profit loss. But the consumer surplus in country H will go up.
The total short run effect on social welfare is ambiguous. If we take into account
considerations of the firm’s R&D, the long-run social welfare in country H is unknown.
Therefore, the policy maker should be cautious about the legalization of parallel trade.
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Discussion
There are several questions that need to be explored further in the future.

Country L’s social welfare function
In this paper, I consider a very basic form of short-run social welfare function for
the government in country L in which includes only consumer surplus. However, the
policy maker very rarely uses such a social welfare function. In reality, there are many
other concerns in the price negotiation process, such as the need for research and
development of pharmaceuticals, containing health care cost and maybe some other
vague political factors. It is difficult to clearly define a social welfare function if we take
into account these long run concerns. Moreover, the social welfare function could change
in the presence of parallel trade. For example, the social welfare function may contain
considerations about the R&D of pharmaceuticals before the presence of parallel trade.
However, in the presence of parallel trade, consumer surplus may become the only
concern of the policy maker in country L because of the higher drug price and budgetary
pressure. If the social welfare function has other components before the presence of
parallel trade, the negotiated price is not the lowest price that the firm will accept. For
example, when the bargaining power all resides with the government in country L, the
equilibrium price would be higher than the firm’s marginal cost. If this is the case, the
social welfare in country L is not necessarily worse off in the presence of parallel trade.
The Profit of the Parallel Trader
Country L also has the opportunity to increase social welfare by extracting profits
from the parallel trader. To induce the firm to continue supplying to market L, the
negotiated price in the presence of parallel trade has to be increased. This will lead to a
certain level of social welfare loss, however, if the loss can be compensated by the profit
extracted from the parallel trader, country L could still be better off.
Bargaining Power
In this study, we assume that the bargaining power is exogenous. In the presence
of parallel trade, the bargaining power may become endogenous. The impact of parallel
trade on the bargaining power of each party in the negotiation needs to be further
explored.
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Appendix

⎧
⎫
⎪
⎪⎪
9 ⎪
(5 + 9α − 4t )
∂p
1. L = ⎨1 −
⎬
∂α 28 ⎪
5 ⎪
2
2
(5 + 9α − 4t ) + 56(t + 2t − )
4 ⎭⎪
⎩⎪
1
∵α > 0 , t <
2
⇒ 5 + 9α − 4t > 1
5
and t 2 + 2t − < 0
4
(5 + 9α − 4t )
⇒
>1
5
2
2
(5 + 9α − 4t ) + 56(t + 2t − )
4
Therefore

∂pL
<0
∂α

⎧
⎫
⎪
⎪⎪
4 ⎪
(5 + 9α − 4t ) − 14(t + 1)
∂p
2. L = − ⎨1 −
⎬
28 ⎪
∂t
5 ⎪
2
2
(5 + 9α − 4t ) + 56(t + 2t − )
⎪⎩
4 ⎪⎭
(5 + 9α − 4t ) − (5 + 9 β )(t + 1)
∵
< −1 (As shown below)
5
(5 + 9α − 4t ) 2 + 4(5 + 9 β )(t 2 + 2t − )
4

∴

∂pL
<0
dt

(5 + 9α − 4t ) − 14(t + 1)
5
(5 + 9α − 4t ) + 56(t + 2t − )
4
2

< −1

2

Proof:

5
4

2
2
2
∵ [(5 + 9α − 4t ) − 14(t + 1)] − [(5 + 9α − 4t ) + 56(t + 2t − )]

⇒ t 2 − 2α (t + 1) + (t 2 + 2t + 1) > 0 , because α < 1
5
4

2
2
∴ (5 + 9α − 4t ) − 14(t + 1) > (5 + 9α − 4t ) + 56(t + 2t − )

Because of the same condition α < 1 , we have
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(5 + 9α − 4t ) − 14(t + 1) < 0
(5 + 9α − 4t ) − (5 + 9 β )(t + 1)
∴
< −1
5
2
2
(5 + 9α − 4t ) + 4(5 + 9 β )(t + 2t − )
4

d ΔpL d ( pL − pLNT ) dpL α
=
=
+ is minimized at γ = 1 when 0 < γ < 1
dγ
dγ
dγ 2

3.

Since
⎧
⎫⎧ ⎡
⎫
⎡
m⎤
m⎤
dpL
) − ⎨Q ( pL ) ⎢π ( pL ) − π ⎥ + π '( pL ) CS ( pL ) ⎬ . ⎨ β ⎢π ( pL ) − π ⎥ − π "( pL ) CS ( pL ) ⎬
dγ
⎣
⎦
⎦
⎭⎩ ⎣
⎭<0
= ⎩
2
Γ
dγ

d(

we know

d Δp L
>0
γ →1 d γ

lim

Therefore
d Δp L
> 0 for 0 < γ < 1
dγ
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Table-1, summary of results

γ

α

γ = 0 γ =1 0 < γ <1 γ = 0 γ =1 0 < γ <1

↓ ↑

↓

↑ ↑
π ↓ ↑

↑

pL
CS

t

-

γ

↓

↓

↓

↑

↑

↑

↑

↑

↑
↑

Decided by

-
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